sintilimab:

Yibo Sun1, Xue Li1, Miaomiao Yang1

  • 1Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, CHN.

Cureus
|November 14, 2025
PubMed
概括

主要的中原黄囊瘤 (PMYST) 是罕见的和积极的. 基于sintilimab的化疗免疫疗法在治疗耐火PMYST方面显示出潜力,为这种具有挑战性的癌症提供了一种新的策略.